Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$-56.43 Mln
EBITDA
$-74.42 Mln
Net Profit
$-51.96 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PAVmed Inc (PAVMW)
| -82.9 | -85.5 | -98.1 | -94.2 | -58.5 | -60.5 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of... adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York. Read more
Chairman & CEO
Dr. Lishan Aklog M.D.
Chairman & CEO
Dr. Lishan Aklog M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PAVmed Inc (PAVMW) is $0.03 (NASDAQ) as of 28-Jan-2022 12:36 EDT. PAVmed Inc (PAVMW) has given a return of -58.51% in the last 3 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2020
|
-303.24
|
5.74
|
|
2019
|
--
|
--
|
|
2018
|
-1.01
|
-7.87
|
|
2017
|
--
|
--
|
|
2016
|
--
|
--
|
The 52-week high and low of PAVmed Inc (PAVMW) are Rs -- and Rs -- as of 05-Apr-2026.
PAVmed Inc (PAVMW) has a market capitalisation of $ 1 Mln as on 14-Feb-2022. As per SEBI classification, it is a company.
Before investing in PAVmed Inc (PAVMW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.